US 12,291,568 B1
Anti-human NR1 antibody derivative
Satoshi Kubo, Tokyo (JP); Atsuo Kanno, Tokyo (JP); Daisuke Yamajuku, Tokyo (JP); Takuya Kito, Tokyo (JP); Masashi Maeda, Tokyo (JP); and Takuma Mihara, Tokyo (JP)
Assigned to ARIALYS THERAPEUTICS, INC., La Jolla, CA (US)
Filed by Arialys Therapeutics, Inc., La Jolla, CA (US)
Filed on Dec. 13, 2024, as Appl. No. 18/981,054.
Application 18/981,054 is a continuation of application No. 18/056,635, filed on Nov. 17, 2022.
Application 18/056,635 is a continuation of application No. PCT/JP2021/019929, filed on May 26, 2021.
Claims priority of application No. 2020-092105 (JP), filed on May 27, 2020.
Int. Cl. C12N 15/13 (2006.01); A61K 39/395 (2006.01); A61P 25/00 (2006.01); C07K 16/28 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/28 (2013.01) [A61P 25/00 (2018.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A one-armed anti-human NR1 antibody comprising: a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), a heavy chain complementarity determining region 3 (HCDR3), a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3), wherein:
the HCDR1 comprising amino acids 31 to 35 of SEQ ID NO: 10, the HCDR2 comprising amino acids 50 to 66 of SEQ ID NO: 10, the HCDR3 comprising amino acids 99 to 111 of SEQ ID NO: 10, the LCDR1 comprising amino acids 24 to 34 of SEQ ID NO: 12, the LCDR2 comprising amino acids 50 to 56 of SEQ ID NO: 12, and the LCDR3 comprising amino acids 89-97 of SEQ ID NO: 12.